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ARTICLE
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halobetasol propionate 0.01%/tazarotene 0.045% lotion for moderate-to-severe
plaque psoriasis
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e
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ABSTRACT

ARTICLE HISTORY

Background: The topical corticosteroid halobetasol propionate (HP) and retinoid tazarotene (TAZ) are
effective in psoriasis treatment. Fixed-combination HP 0.01%/TAZ 0.045% lotion has demonstrated
efficacy and safety in moderate-to-severe plaque psoriasis.
Objective: To investigate the maintenance of therapeutic effects after cessation of once-daily HP/
TAZ treatment.
Methods: In two phase 3 studies (NCT02462070; NCT02462122), adults with moderate-to-severe psoriasis received HP/TAZ for 8 weeks. Data at week 12 were analyzed post hoc to evaluate posttreatment
maintenance of treatment success (clear/almost clear skin), improvements in signs of psoriasis (erythema, plaque elevation, scaling), and reductions in affected body surface area (BSA). In a 52-week
open-label study (NCT02462083), participants stopped HP/TAZ treatment after achievement of treatment success; data were analyzed post hoc to assess time to retreatment.
Results: Across all studies, most participants who achieved treatment success maintained this effect
for at least one month posttreatment. Treatment effects were similarly maintained for improvements
in signs of psoriasis and reductions in BSA. Some participants continued to improve after cessation of
treatment. Maintenance of treatment success and time to retreatment were greater for participants
who achieved clear skin.
Conclusion: HP/TAZ lotion provides therapeutic effects that persist after treatment cessation, supporting its use in long-term management of plaque psoriasis.
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Introduction
Psoriasis is a lifelong inflammatory skin condition in which
periods of remission are punctuated by relapse or disease flare.
For approximately 80% of patients with psoriasis, topical therapies are the first line of treatment (1). Prolonged use of many
topical therapies is associated with safety concerns, however,
posing a major challenge to the long-term management of
this chronic disease. Thus, there is an ongoing need for psoriasis treatments providing therapeutic benefits that persist long
after treatment cessation, thereby increasing the duration of
disease remission.
Topical corticosteroids (TCS) are a mainstay of psoriasis treatment, providing rapid, anti-inflammatory actions (2). However,
despite the chronic nature of psoriasis, safety concerns limit continuous use of most TCS to 2–4 weeks (3) and only one TCS – halobetasol propionate (HP) 0.01% lotion – is approved for 8 weeks
of continuous use (4). Moreover, discontinuation of TCS use is
associated with relapse or rebound effects (3). The retinoid tazarotene (TAZ) is as efficacious as topical corticosteroids, with therapeutic benefits persisting for up to 12 weeks after treatment
cessation (5). However, TAZ monotherapy may be underutilized
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in the clinic due to irritation concerns (6). The combination of
TAZ with a potent-to-superpotent TCS has been shown to be
more efficacious and to provide greater duration of therapeutic
effects after treatment cessation than either TAZ or TCS monotherapy, and is associated with fewer safety concerns (2,7,8).
A fixed-combination HP 0.01%/TAZ 0.045% lotion (HP/TAZ;
DuobriiV; Ortho Dermatologics, Bridgewater, NJ, USA) was developed to leverage the beneficial properties of both active ingredients, while mitigating safety concerns, in a single easy-to-use
formulation (6). HP/TAZ lotion provides greater permeation efficiency of the active ingredients compared with higher-dose HP
or TAZ creams (alone or layered) (6) with reduced potential for
irritation and other adverse events (9). Overall efficacy and safety
results for HP/TAZ lotion from two phase 3 randomized clinical
trials and a 52-week, long-term open-label study have been presented in detail (10–13). The objective of the post hoc analyses
presented here was to evaluate the maintenance of therapeutic
effects with HP/TAZ lotion by assessing efficacy 4 weeks posttreatment in the phase 3 studies, and the time to retreatment
after HP/TAZ cessation in the long-term open-label study.
R
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Materials and methods
Overview of studies and participants
All studies were performed at multiple study centers in the
United States in accordance with ethical principles from the
Declaration of Helsinki, International Conference on
Harmonization guidelines, Good Clinical Practice, and local regulatory requirements. Institutional review boards or ethics panels
approved the protocols at all sites. All participants provided
written informed consent prior to any study-related procedures,
including permission for their photos to be used for non-promotional purposes.
For all studies, key inclusion criteria were an age of 18 years
and diagnosis of moderate-to-severe plaque psoriasis, defined
as an Investigator’s Global Assessment (IGA) score of 3 or 4 (5point scale; 0 ¼ clear, 1 ¼ almost clear; 2 ¼ mild; 3 ¼ moderate;
4 ¼ severe) and an affected body surface area (BSA) of 3–12%,
excluding involvement of the face, scalp, palms, soles, axillae,
and intertriginous areas. CeraVeV hydrating cleanser and
CeraVeV moisturizing lotion (L’Oreal, NY) were provided for
optional use as needed for moisturization/cleaning of the skin.
R

R

were evaluated for treatment success, defined as an IGA score
of 0 (clear) or 1 (almost clear). Those who achieved treatment
success stopped treatment for 4 weeks; those who did not
achieve treatment success continued treatment for 4 weeks. At
week 12, participants who had not achieved 1-grade improvement from baseline IGA were discontinued from the study.
Maximum continuous exposure during the study was 24 weeks;
if 24 weeks of continuous treatment had been received at any
point in the study, the participant needed an IGA score of 0 or
1 to continue the study.
Participants enrolled for at least 8 weeks in this study and
who stopped HP/TAZ therapy after achieving treatment success
were assessed for maintenance of treatment success, defined as
the time to retreatment with HP/TAZ. This was evaluated separately for participants who achieved an IGA score of 0 (clear) and
for those who achieved an IGA score of 1 (almost clear).
Maintenance of effect was measured as the cumulative percentage of participants who remained treatment successes for more
than 4, 8, 12, and 16 weeks, or until end of study (i.e. no
relapse) after cessation of HP/TAZ treatment. As with the pooled
phase 3 studies, all analyses were descriptive in nature and statistical comparisons were not performed.

Pooled phase 3 studies
Data from 2 multicenter, randomized, double-blind, vehicle-controlled phase 3 studies (NCT02462070; NCT02462122) were
pooled for analysis. Study designs have been described previously (10,11); briefly, participants were randomized (2:1) to
receive HP/TAZ or vehicle lotion once daily for 8 weeks with a
4-week posttreatment follow-up visit at week 12.
The primary efficacy endpoint in these studies was treatment
success, defined as a 2-grade improvement from baseline IGA
score and a score of 0 (clear) or 1 (almost clear) at week 8.
Secondary efficacy endpoints included change from baseline in
affected BSA and treatment success at the target lesion for individual signs of psoriasis (erythema, plaque elevation, and scaling), defined as a 2-grade improvement from baseline in
severity (5-point scale; 0 ¼ none, 4 ¼ severe).
Multiple shift analyses were performed to determine participants who maintained or gained treatment effects at week 12
(4 weeks posttreatment). For treatment success (overall and individual signs of psoriasis), maintenance of treatment effect was
defined as the percentage of participants achieving success at
week 8 who also achieved success at posttreatment follow-up
(week 12); gain of treatment effect was defined as the percentage of participants who had not achieved success at week 8 but
who achieved success posttreatment. Shifts in IGA score from
week 8 to week 12 were also measured to gauge posttreatment
maintenance or improvement of psoriasis severity. Maintenance
of affected BSA was assessed as the percentage of participants
whose BSA remained the same or decreased from week 8 to
week 12. All analyses were descriptive in nature; as such, statistical comparisons were not performed.
Long-term open-label phase 3 study
The details of this 1-year, multicenter, open-label study
(NCT02462083) have been described previously (12). Briefly, participants were treated with HP/TAZ lotion once daily for
8 weeks; for the remainder of the 52-week study, treatment was
used intermittently, as needed, in 4-week intervals. At week 8
and all subsequent study visits (every 4 weeks), participants

Results
Posttreatment maintenance or gain of treatment effect with
HP/TAZ lotion (pooled phase 3 studies)
A total of 276 participants were randomized to HP/TAZ lotion
treatment and included in the pooled intent-to-treat (ITT) population. Demographics, baseline characteristics, and disposition of
these participants have been described previously (10,11).
Briefly, mean age was 50.0 years, 36.6% were female, 84.1%
were White, and 71.7% were not Hispanic or Latino; at baseline,
85.9% had an IGA score of 3 (moderate), and mean BSA
was 6.0%.
In the overall study population, 40.6% of HP/TAZ-treated participants achieved treatment success at week 8 and 33.3%
achieved treatment success at week 12 (using multiple imputation of missing values) (11). Maintenance and gain of treatment
effect were assessed for 234 participants for whom week 8 and
week 12 efficacy results were available (Figure 1). Of those who
had achieved treatment success at week 8 (n ¼ 101), 62.4%
maintained treatment success at week 12 (4 weeks posttreatment); of those who had not achieved treatment success at
week 8 (n ¼ 133), 18 participants (13.5%) gained treatment success at week 12. Representative images of participants who
experienced posttreatment maintenance or gain of treatment
success are shown in Figures 2 and 3, respectively.
Regardless of treatment success outcomes at week 8, the
majority of participants experienced posttreatment maintenance
or improvement in psoriasis severity at 4 weeks posttreatment
(week 12; Figure 4). Of the 16 participants who had an IGA
score of clear at week 8, half maintained clear at week 12 and
31.3% were almost clear; overall, over 80% remained treatment
successes. Among the 85 participants who were almost clear at
week 8, half maintained almost clear and 8.2% improved to
clear at week 12; overall, almost 60% of these participants
remained treatment successes. Improvements in psoriasis severity were also seen in participants who were mild or moderate at
week 8. Of 82 participants who were mild at week 8, 15.8%
improved to clear or almost clear (45% maintained mild); of 50
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participants who were moderate at week 8, 10% improved to
clear or almost clear and 10% improved to mild (two-thirds
maintained moderate). One participant was severe at week 8
and remained severe at week 12.
For individual signs of psoriasis (erythema, plaque elevation,
and scaling) assessed in the overall study population, treatment
success was achieved by 47.0–61.2% of participants at week 8
and by 43.4–51.4% of participants at week 12 (11). Similar to
overall treatment success, the majority (69.6–74.1%) of participants who achieved treatment success in signs of psoriasis at

Figure 1. Maintenance or gain of treatment success 4 weeks posttreatment
with HP/TAZ lotion (pooled phase 3 studies). Treatment success was defined
as 2-grade improvement from baseline IGA and a score of 0 (clear) or 1
(almost clear). Data shown for Week 12 treatment success, stratified by participants with or without week 8 treatment success. HP/TAZ: halobetasol propionate 0.01% and tazarotene 0.045%; IGA: Investigator’s Global Assessment.

3

week 8 maintained this effect 4 weeks posttreatment; among
participants who did not achieve success at week 8, 12.6–20.5%
gained success at week 12 (Figure 5).
Overall, there was a 37.6% reduction from baseline in mean
BSA among HP/TAZ-treated participants at week 8, and a 34.1%
reduction from baseline at week 12 (11). BSA involvement was
maintained or reduced (improved) from week 8 to week 12 in
almost three-quarters (73.5%) of participants.
Time to retreatment after cessation of treatment with HP/TAZ
lotion (long-term open-label phase 3 study)
In this study, 555 participants were treated with HP/TAZ lotion
and 550 had post-baseline safety data. Detailed participant
demographics, baseline characteristics, and disposition have
been described previously (12). Participants were generally similar to those in the pooled phase 3 studies. Mean age was
51.9 years, 34.4% were female, 86.0% were White, and 74.4%
were not Hispanic or Latino; at baseline, 86.5% had an IGA score
of 3 (moderate), and mean BSA was 5.6%.
Overall, 318 participants (57.8%) achieved treatment success
(IGA score of 0 [clear] or 1 [almost clear]) at some point during
this study (12). Consistent with the results of the pooled phase
3 studies, the majority of participants experienced maintenance
of treatment success after cessation of HP/TAZ treatment. Of
226 participants enrolled at least 8 weeks in the study and who
stopped therapy after achieving treatment success, time to
retreatment was more than 4 weeks for 55.3%, more than
8 weeks for 28.3%, more than 12 weeks for 19.5%, and more
than 16 weeks for 12.4%; 6.6% did not relapse for the duration
of the study and therefore did not require any retreatment (12).
Mean and median times to relapse were 61.0 and 30.0 days,
respectively.
Per study protocol, participants stopped HP/TAZ treatment
(until their next assessment) upon achievement of clear or
almost clear skin (14). Duration of remission may have been
greater, however, if all participants had been allowed to continue HP/TAZ treatment until achieving clear skin, which better
aligns with dosage and administration guidelines in the prescribing information (‘discontinue treatment when control is
achieved’) (14). To evaluate this possibility, we performed

Figure 2. Posttreatment maintenance of treatment success with HP/TAZ lotion. Treatment success was defined as 2-grade improvement from baseline IGA and
a score of 0 (clear) or 1 (almost clear). Representative images from a participant with target lesion on the lower back. Participant IGA: baseline, 3; weeks 8 and
12, 1. Participant BSA: baseline, 11%; week 8, 11%; week 12, 3%. BSA: body surface area; HP/TAZ: halobetasol propionate 0.01% and tazarotene 0.045%; IGA:
Investigator’s Global Assessment.
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Figure 3. Posttreatment gain of treatment success with HP/TAZ lotion. Treatment success was defined as 2-grade improvement from baseline IGA and a score
of 0 (clear) or 1 (almost clear). Representative images from a participant with target and non-target lesions on the lower leg. aLesions indicated by white stickers
on participant’s leg; target lesion indicated by sticker with letter ‘T’. Participant IGA: baseline, 3; week 8, 2; week 12, 0. Participant BSA: baseline, 6%; week 8, 4%;
week 12, 0%. BSA: body surface area; HP/TAZ: halobetasol propionate 0.01% and tazarotene 0.045%; IGA: Investigator’s Global Assessment.

Figure 4. Posttreatment IGA severity by week 8 results (pooled phase 3 studies). aRemained severe at week 12. IGA assessed on a 5-point scale: 0 ¼ clear,
1 ¼ almost clear; 2 ¼ mild; 3 ¼ moderate; 4 ¼ severe. Treatment success defined as 2-grade improvement from baseline IGA and a score of 0 (clear) or 1 (almost
clear). IGA: Investigator’s Global Assessment.

separate analyses of maintenance of treatment success for participants who achieved clear skin and participants who achieved
almost clear skin (Figure 6). Of the 56 (24.8%) participants who
achieved clear skin, 83.9% did not require retreatment for more
than 4 weeks, 62.5% for more than 8 weeks, 53.6% for more
than 12 weeks, and 39.3% for more than 16 weeks; 28.6% did
not relapse for the duration of the study and therefore did not
require any retreatment. Mean and median times to relapse for
these participants were 104.7 days and 85.0 days, respectively.
Among the 170 (75.2%) participants who achieved treatment
success with almost clear skin, the duration of posttreatment
effect was shorter than for participants who achieved clear skin
(Figure 6).

Discussion
In the treatment of psoriasis, the importance of providing sustained therapeutic effects and increasing time in remission cannot be understated, as it is a chronic disease that frequently

recurs after discontinuation of treatment (2). Lower rates of
relapse and disease flare are associated with improved quality
of life and lower levels of productivity loss (15), underscoring
the ongoing need for therapies that provide durable therapeutic
benefits. Increasing posttreatment maintenance of effects would
have the added benefit of reducing overall drug exposure, thus
potentially reducing treatment-related safety and tolerability
concerns. However, in a survey of patient satisfaction, only onethird of respondents currently using topical treatments rated
their treatment positively (good/very good/excellent) for not losing effectiveness over time or for making them feel like their
psoriasis was under control (16). Indeed, patients are frequently
dissatisfied with their psoriasis treatment, despite the expansion
of treatment options available, because therapies too often fail
to achieve or maintain skin clearance (17).
Combining topical therapies can improve outcomes in the
treatment of psoriasis. In a clinical trial, fixed-combination HP/
TAZ lotion provided greater efficacy in the treatment of moderate-to-severe psoriasis than HP or TAZ alone (18). The present
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Figure 5. Signs of psoriasis maintenance or gain of treatment success 4 weeks posttreatment with HP/TAZ lotion (pooled phase 3 studies). Treatment success
was defined as 2-grade improvement from baseline in individual signs of psoriasis at the target lesion. Data shown for Week 12 success, stratified by participants with or without week 8 success. HP/TAZ: halobetasol propionate 0.01% and tazarotene 0.045%; IGA: Investigator’s Global Assessment.

Figure 6. Maintenance of treatment success (long-term open-label study). Data shown for participants enrolled at least 8 weeks in the study and who stopped
therapy after achieving treatment success, defined as an IGA score of 0 (clear) or 1 (almost clear). Cumulative data shown; within each subgroup, participants
included in each bar are not mutually exclusive. Number of weeks to retreatment based on a 7-day week: 4 weeks ¼ 28 days; 8 weeks ¼ 56 days; 12 weeks ¼
84 days; 16 weeks ¼ 112 days. IGA: Investigator’s Global Assessment.

analyses assessed the maintenance of treatment effects after
cessation of HP/TAZ treatment. In two phase 3 studies, the
majority of participants who achieved treatment success after
8 weeks of treatment continued to experience treatment success
4 weeks posttreatment. Additionally, some HP/TAZ-treated participants who did not achieve treatment success after 8 weeks
continued to improve and achieved treatment success 4 weeks
posttreatment. Similar findings were observed for psoriasis

severity, signs of psoriasis, and BSA involvement. In a 52-week
open-label study, the majority of participants experiencing treatment success did not require retreatment for over 4 weeks, with
many experiencing much longer (>16 weeks) maintenance of
treatment success.
The posttreatment duration of disease remission can be
increased by treating psoriasis until achievement of clear skin. In
the pooled phase 3 clinical trials of HP/TAZ lotion, a greater
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percentage of participants who achieved clear skin maintained
treatment success 4 weeks posttreatment compared with participants who achieved almost clear skin (81.3% versus 58.7%,
respectively). In the long-term open-label study, the median
time to relapse/retreatment was 55 days longer for participants
who achieved clear skin versus those who achieved treatment
success (clear or almost clear skin). These efficacy data align
with patient-reported outcomes, in which individuals with clear
skin are more likely to report no impact of psoriasis on quality
of life than those with almost clear skin (17). Moreover, drug
efficacy can have a strong impact on patients’ preferences for
and satisfaction with topical psoriasis therapies (19), which in
turn can profoundly affect adherence to treatment and overall
treatment success. Thus, treating to clear skin and increasing
the posttreatment duration of therapeutic effects may improve
patient satisfaction and quality of life.
One challenge to the interpretation of these findings is that
protocol-defined treatment regimens in the clinical trials do not
represent real-world use of HP/TAZ lotion. Treatment until
achievement of clear skin reflects the goals of both patients and
clinicians in a real-world setting, and the prescribing information
for HP/TAZ lotion indicates that daily treatment should continue
until control is achieved, without providing any limitations on
the duration of treatment (14). In the long-term open-label
study, however, participants were required to stop treatment if
they achieved almost clear skin. Allowing treatment to continue
until achievement of clear skin would potentially have yielded a
longer maintenance of treatment effect. This is supported by
the comparison of participants who achieved clear versus
almost clear, in which a greater percentage of participants with
clear skin did not require retreatment and were able to maintain
treatment success for longer periods of time. In contrast to the
flexible dosing of the long-term study, participants in the
pooled phase 3 studies were required to stop treatment after a
fixed 8-week treatment period, regardless of treatment success
status; however, it is possible that more participants could have
achieved treatment success with continued treatment
past 8 weeks.
The fixed 8-week treatment regimen in the pooled phase 3
studies may also have led to inflated incidences of adverse
events (AEs). Many participants in these studies achieved treatment success within the first 2–4 weeks of treatment but were
required to continue treatment through 8 weeks (10,11); this
continued treatment could have increased the likelihood of irritation and other adverse effects of prolonged TAZ or TCS exposure. In these studies, most AEs were of mild or moderate
severity and the most common treatment-related AEs were contact dermatitis, pruritus, and application site pain (10,11). With
longer-term treatment in the open-label study, rates of these
AEs decreased to less than 1% after week 36 (12,13). Incidences
of skin atrophy with HP/TAZ lotion were rare, even with up to
24 weeks of continuous treatment in the long-term open-label
study (10–13). HP/TAZ treatment was also associated with
reductions in the severity of itching, dryness, and burning/stinging skin symptoms across the phase 3 and open-label studies
(10,11). Although HP/TAZ lotion has demonstrated a favorable
safety profile with up to 24 continuous weeks of use, treatmentrelated irritation remains a concern for clinical use (9). Irritation
can be mitigated by temporarily interrupting drug use (i.e. drug
holiday) until irritation signs and symptoms have subsided. In
addition, use of moisturizers concurrent with treatment and/or
during periods of irritation-related treatment cessation can

enhance epidermal barrier function and counteract adverse
effects of prolonged TAZ and TCS exposure (20,21).
A benefit of the 52-week open-label study is that it allowed
for the evaluation of up to 24 weeks of continuous treatment
with a superpotent TCS with long-term follow-up; this is especially noteworthy given the lack of long-term (>6 months) clinical trials evaluating posttreatment maintenance of efficacy for
TCS and other topical psoriasis therapies (22). In one other 52week open-label study, a fixed-combination foam – containing
the corticosteroid betamethasone dipropionate and the vitamin
D analog calcipotriene (Cal/BD) – was assessed for time in
remission after cessation of once-daily treatment (23).
Participants were treated to clear or almost clear skin and then
either stopped treatment entirely until relapse or continued
treatment with twice-weekly Cal/BD to prevent relapse. Among
participants who stopped treatment entirely, the median time
to first relapse was 30 days, similar to the overall median time
to retreatment in the long-term open-label study of HP/TAZ
lotion; prophylactic, twice-weekly Cal/BD treatment extended
this time to first relapse to 56 days. In comparison, participants
who stopped HP/TAZ treatment entirely after achievement of
clear skin had a median time to relapse of 85 days. Thus, treatment to clear skin with HP/TAZ lotion was associated with a
duration of remission that was longer than that seen with continued bi-weekly treatment with Cal/BD foam. This difference
highlights both the importance of treatment to clear skin and
the unique mechanism of action by which TAZ may contribute
to the maintenance of treatment effects. TAZ addresses the
pathophysiology of psoriasis by normalizing keratinocyte proliferation/differentiation, reducing immune cell infiltration, and
decreasing the expression of proinflammatory markers, and is
thus thought to return skin to a quiescent, ‘prelesional’
state (24,25).

Conclusion
In clinical trials, fixed-combination HP/TAZ lotion has consistently demonstrated greater efficacy over placebo and a favorable safety profile (10,11). The beneficial effects of HP/TAZ
lotion were maintained for at least one month in the majority
of participants who achieved clear or almost clear skin, and
some participants gained treatment success after cessation of
treatment. These results support the use of fixed-combination
HP/TAZ lotion for the long-term treatment and management of
plaque psoriasis.
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